MADRID, Nov 10 (APM) - Following media reports that Barcelona’s bid to host the European Medicines Agency after Brexit is "dead" and that Bratislava and Milan are leading the race, the Spanish health minister has denied this is the case, it is being widely reported in the Spanish press on Friday.
Diplomatic sources have told the FT Barcelona is out due to the political tension in the region, daily El Mundo reports.
The final vote to decide on the relocation of the agency will take place on November 20, but instability has boosted Milan’s candidacy, the newspaper adds.
La Razón reports that Barcelona was the front-runner before the independence process started.
Financial paper Expansión says Amsterdam and Copenhagen are also strong competitors.
EMA employs 900 people and has generated around 1,600 companies which provide different services to it, the financial says.
El País carries a short editorial saying the agency will probably move to Amsterdam or Milan, with Dutch and Italian citizens clapping with glee while Barcelona will go back to being “the small provincial town it was in the past”.
La Vanguardia quoted a Twitter comment by health minister Dolors Montserrat as saying: “We are still working” to bring EMA to Barcelona.
Gaceta Médica quoted Montserrat as saying: “The Spanish government is defending Barcelona’s great candidacy to host the European Medicines Agency”. Montserrat said the election is quite fragmented, with 19 candidates. “It is impossible to say, based on objective data, which is the candidate with the best shot,” she said.
Financial Cinco Días, daily El Diario and medical journal Redacción Médica also carry the story on Friday.
PharmaMar expects negative review for Aplidin
Spain’s PharMamar has informed the agency which supervises the country's stock market, CNMV, that it is expecting a negative opinion by the European Medicines Agency’s CHMP on its multiple myeloma drug Aplidin (plitidepsin), financial Cinco Días and daily El Periódico reported on Thursday.
In a statement sent to the agency, the company said the CHMP's decision comes as a surprise, Cinco Días reported.
On Friday, financial Expansión carries a follow-up reporting PharmaMar’s shares plummeted 33% two and a half hours after the company disclosed this information.
According to Expansión, this drawback overshadows previous increases during the year, leaving PharmaMar with a 19.7% annual drop in shares.
Pharma commits to making Spain attractive to investors
Humberto Arnés, general director of Spanish branded pharma lobby Farmaindustria, has said pharmaceutical companies operating in Spain are committed to making the country an attractive place to invest and research, financial El Economista reported on Wednesday.
Speaking at the Royal National Medicine Academy (RANM) on Tuesday, Arnés said pharma is the leading industry by R&D investment, with over 1 billion euros in 2016. He also noted that a substantial portion of this investment is devoted to public-private partnerships. (APMHE 53919
The group’s efforts to promote these initiatives, together with pharma-biotech cooperation and biomedical research, were presented by Arnés as examples of Farmaindustria’s commitment, the financial noted.
Inexpensive drug could save thousands of lives
British researchers suggest rapid treatment with tranexamic acid, which costs less than four euros, could reduce risk of death by 70% in people with severe bleeding, daily ABC reported on Thursday.
In a meta-analysis of trials on the drug published in the Lancet, researchers say time is key in these cases. According to this study, for every 15-minute delay in treatment, survival benefit was cut by about 10%, ABC reported.
Every year, more than 2 million people worldwide die from traumatic extracranial bleeding. Postpartum haemorrhage is the leading cause of maternal death worldwide, killing around 100,000 women a year, ABC noted.
Pfizer presents Cresemba in Spain
Pfizer has started the commercialisation of antifungal drug Cresemba (isavuconazonium sulfate) in Spain, medical journal Acta Sanitaria reported on Wednesday.
Cresemba is approved in adult patients with two serious infections, invasive aspergillosis and mucormycosis. This is Pfizer’s first European subsidiary to launch the drug following a 444 million-euro deal with the drug's original developer Basilea Pharmaceutica, the journal noted.
Medical journal IM Médico Hospitalario carries the story on Friday.